Eptifibatide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Eptifibatide: From Acute Coronary Syndrome to Rheumatoid Arthritis
One-Sentence Summary
Eptifibatide is a cyclic peptide GPIIb/IIIa (αIIbβ3 integrin) antagonist, clinically established for reducing thrombotic events in acute coronary syndromes (ACS). The TxGNN model assigns its highest repurposing score to Rheumatoid Arthritis, but this connection is currently supported by no clinical trials and no published literature. Notably, among all predictions in this evidence pack, Hemoglobinopathy (Sickle Cell Disease) carries the most substantive evidence base — 1 Phase I/II randomized trial and 4 publications — and warrants prioritized clinical review.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute Coronary Syndrome / UA/NSTEMI (not registered in Canada) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in this evidence pack (flagged as a high-severity data gap). Based on established pharmacology, eptifibatide is a synthetic cyclic heptapeptide (KGD motif) that selectively antagonizes the GPIIb/IIIa (αIIbβ3 integrin) receptor on platelets — the final common pathway of platelet aggregation. It is delivered intravenously and is standard-of-care for ACS patients (UA/NSTEMI) undergoing percutaneous coronary intervention.
The mechanistic case for rheumatoid arthritis is highly theoretical. Platelets are increasingly recognized as participants in synovial inflammation: activated platelets can shed microparticles bearing αIIbβ3, P-selectin, and pro-inflammatory phospholipids that interact with immune effector cells in the joint. Blocking αIIbβ3 could theoretically dampen this platelet-driven inflammatory amplification. However, no direct preclinical or clinical studies have evaluated this hypothesis in RA specifically.
The TxGNN model’s near-perfect score most likely reflects non-specific connectivity between immunovascular nodes in the underlying knowledge graph rather than a direct drug-target-disease relationship. This prediction should be treated as hypothesis-generating only — a starting point for basic science inquiry, not a clinical development priority.
Clinical Trial Evidence
Currently no related clinical trials registered for Eptifibatide in Rheumatoid Arthritis.
Literature Evidence
Currently no related literature available for Eptifibatide in Rheumatoid Arthritis.
Canada Market Information
Eptifibatide is not currently registered in Canada. There are no DINs on file and no Health Canada-licensed products. Any clinical use in Canada would require a Special Access Programme (SAP) authorization.
Safety Considerations
Safety profile data (key warnings, contraindications, drug interactions) was not available in this evidence pack. Please refer to the original product monograph (e.g., Integrilin®) and Health Canada’s drug product database for comprehensive prescribing safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The RA prediction rests entirely on model inference (L5), with no supporting preclinical or clinical evidence; the theoretical platelet-synovitis mechanism has not been tested in any published study, and eptifibatide’s IV-only route is poorly suited to a chronic inflammatory condition like RA.
To proceed, the following is needed:
- Preclinical proof-of-concept: In vitro or animal model studies examining eptifibatide’s effect on platelet-synoviocyte interactions in RA models
- MOA data gap closure: Retrieve full mechanism of action and pharmacodynamic profile from DrugBank API (DG002)
- Safety data gap closure: Download and parse TFDA/Health Canada product monograph for warnings and contraindications (DG001)
⚠️ Higher-Priority Signal Identified
Within this same evidence pack, Hemoglobinopathy / Sickle Cell Disease (rank 7 by TxGNN, evidence level L3) has a substantially stronger evidentiary foundation and should be reviewed separately:
Trial Phase Status Enrollment NCT00834899 Phase I/II RCT Terminated 13
PMID Year Type Key Finding 17916103 2007 Phase I Study Safety/PD data confirmed in 4 SCA patients; αIIbβ3 inhibition rationale established 23973010 2013 Pilot Study Safety and efficacy assessed during acute pain episodes in SCD 29322543 2018 Pilot Study Inflammatory marker reduction observed during acute SCD pain episodes 22156199 2012 In Vitro Microfluidic model recapitulated SCD microvascular occlusion The αIIbβ3-mediated platelet–sickle erythrocyte–endothelium interaction is mechanistically well-supported, and the existing clinical signals — though from small, early-phase studies — justify a formal Research Question evaluation with a dedicated evidence pack.
This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.